Danske Bank kommentar till pressmeddelande 2019-09-24

Zenicor – Deal with UK CCG an important step in European expansion

While the deal is an important contribution to sales, representing 4% of our current sales estimates in 2019E, the deal shows that CCGs are willing to implement a new, digitalized, care pathway (i e Zenicor’s thumb ECG vs current standard of use).

We see the deal as particularly important in terms of both an UK and European market opening and thus as a relieving factor for significant market penetration ahead. We argue a key driver for signing this contract is Zenior’s participation in the NHS backed SAFER study, validating the product. As there are as much as 191 CCGs within NHS England, we see a high probability of Zenicor gradually signing additional contracts with CCGs, supporting top-line growth.

Fullständig version från Danske Bank